Literature DB >> 16426919

The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis.

Christine Ann Davies1, Maria Jeziorska, Anthony J Freemont, Ariane L Herrick.   

Abstract

Our aim was to evaluate (a) whether there is differential expression of the endothelial regulator vascular endothelial growth factor (VEGF), its receptor (VEGFR-2), and the hypoxia-associated glucose transporter molecule, GLUT-1, in skin biopsies from different disease subtypes of systemic sclerosis (SSc) and (b) whether they associate with dermal calcinosis, a significant complication of SSc. Skin punch biopsies were taken from the forearms of 66 SSc patients including 18 with limited cutaneous disease without calcinosis (lcSSc), 23 with calcinosis (lcSSc/cal), and 25 with diffuse cutaneous disease (dcSSc) and from 12 healthy control subjects. The histological appearance of the skin was graded as G0 (normal), G1 (dermal edema), or G2 or G3 (increasing fibrotic changes). Immunohistochemistry was performed with antibodies to VEGF, VEGFR-2, and GLUT-1. Staining was assessed in the epidermis, microvessels, and fibroblasts. The Kruskal-Wallis 1-way analysis of variance was used to compare the data between disease groups. VEGF protein was located in the epidermis and in dermal endothelial cells, pericytes, fibroblasts, and inflammatory cells. In dcSSc only, there was a significant increase in VEGF staining intensity in the keratinocytes and pericytes and the lowest percentage of microvessels with VEGF-positive endothelial cells. GLUT-1 protein was located in the epidermis, erythrocytes, and perineurium. In both lcSSc/cal and dcSSC, but not lcSSc, there were significant increases in GLUT-1 staining intensity of keratinocytes. We propose that in patients with dcSSc, there is a net increase in unbound VEGF in skin that may account for the raised levels of VEGF in serum reported by others. Increased GLUT-1 expression in lcSSc/cal and dcSSc indicates that hypoxia is an associated factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16426919     DOI: 10.1016/j.humpath.2005.10.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

Review 1.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

2.  Paraspinal tumoral calcinosis in a child with systemic sclerosis/myositis overlap.

Authors:  Nicole Dray; Anil G Rao; Richard M Silver
Journal:  Pediatr Radiol       Date:  2011-07-07

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 4.  Is there evidence for vasculitis in systemic sclerosis?

Authors:  Lesley Ann Saketkoo; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 5.  [Current pathophysiological aspects of systemic sclerosis].

Authors:  T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 6.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

7.  Serum levels of leptin receptor in patients with systemic sclerosis.

Authors:  Yukimi Ohyoshi; Takamitsu Makino; Masatoshi Jinnin; Wakana Nakayama; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Intractable Rare Dis Res       Date:  2013-05

Review 8.  Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts.

Authors:  Bradley J Rabquer; Alisa E Koch
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

9.  Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis.

Authors:  Shervin Assassi; William R Swindell; Minghua Wu; Filemon D Tan; Dinesh Khanna; Daniel E Furst; Donald P Tashkin; Richard R Jahan-Tigh; Maureen D Mayes; Johann E Gudjonsson; Jeffrey T Chang
Journal:  Arthritis Rheumatol       Date:  2015-11       Impact factor: 10.995

Review 10.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.